文献速递临床试验与 GCP流行病学与生物统计

omega-3与维生素D联合补充对糖尿病前期合并维生素D缺乏育龄女性心脏代谢风险和心理困扰影响的研究方案:随机对照试验

The effect of co supplementation of omega-3 and vitamin D on cardio metabolic risk factors and psychological distress in reproductive-aged women with prediabetes and hypovitaminosis D: a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-12-30

该随机对照试验旨在确定omega-3和维生素D联合补充对糖尿病前期合并维生素D缺乏的育龄女性空腹血糖、其他心脏代谢风险因素和心理困扰的影响。采用2×2析因、三盲、安慰剂对照设计,纳入168名女性,随机分为四组,干预八周。主要目的是评估这些补充剂对血糖指标、血脂、心理困扰、血压和人体测量指标的效果,为预防或延缓2型糖尿病提供证据。

要点

  • 2×2析因三盲安慰剂对照试验,纳入168名糖尿病前期合并维生素D缺乏的育龄女性。
  • 干预八周:omega-3脂肪酸1000 mg每日两次,维生素D 50,000 IU每两周一次。
  • 主要结局包括血糖指标、血脂、心理困扰、血压和人体测量指标。

核心结论

  • 本试验旨在确定维生素D和/或omega-3对糖尿病前期合并维生素D缺乏女性血糖指标、血脂、心理困扰、血压和人体测量指标的影响。

研究设计与样本

  • 2×2析因、三盲、随机、安慰剂对照临床试验,纳入168名糖尿病前期合并维生素D缺乏的育龄女性,干预八周。
  • 参与者随机均分至四组:omega-3脂肪酸1000 mg每日两次+维生素D安慰剂每两周;omega-3安慰剂每日两次+维生素D 50,000 IU每两周;omega-3脂肪酸1000 mg每日两次+维生素D 50,000 IU每两周;双安慰剂。

关键数值与推荐

  • omega-3脂肪酸剂量为1000 mg,每日两次;维生素D剂量为50,000 IU,每两周一次;干预时长八周。
  • 主要结局指标包括血清血糖指标(空腹血糖、胰岛素、HOMA-IR、HOMA-β)、血脂(甘油三酯、LDL-C、HDL-C、总胆固醇)和维生素D状态。
  • 心理困扰采用抑郁焦虑压力量表21(DASS-21)和匹兹堡睡眠质量指数(PSQI)评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A prediabetic state is a risk factor for type 2 diabetes. There are no approved drugs to manage prediabetes. Among the supplements routinely used by individuals, vitamin D and omega-3 have been studied to reduce fasting blood sugar. However, their co-supplementation has not been studied in individuals with prediabetes. This randomized controlled trial is designed to determine the effects of these two supplements on fasting blood sugar, other cardio metabolic risk factors, and psychological distress in reproductive-aged women with prediabetes and hypovitaminosis D. METHODS/DESIGN: This 2 × 2 factorial, triple-blind, randomized, placebo-controlled, clinical trial will be done on 168 women of reproductive age diagnosed with prediabetes and hypovitaminosis D. Participants will be randomly assigned equally to four groups: (1) 1000 mg omega-3 fatty acid twice a day + vitamin D placebo every two weeks; (2) omega-3 fatty acid placebo twice a day + 50,000 IU vitamin D every two weeks; (3) 1000 mg omega-3 fatty acid twice a day + 50,000 IU vitamin D every two weeks; (4) omega-3 fatty acid placebo twice a day + vitamin D placebo every two weeks for eight weeks. At the beginning, participants will provide a self-reported questionnaire on the sociodemographic characteristics. At baseline and post-intervention visits, physical activity, Depression Anxiety Stress Scale 21 and Pittsburgh Sleep Quality Index, and a three-day food record will be collected for each individual. Blood pressure, weight, height, and waist circumference will also be measured. At the beginning and at the end, a blood sample will be used for estimating serum glucose indices (fasting blood sugar and insulin, homeostasis model assessment-insulin resistance, homeostasis model assessment-beta cell function), lipids (triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total cholesterol), and vitamin D status. Data analysis using Kolmogorov-Smirnov test, paired t-test, one-way analysis of variance, and repeated measures analysis of variance will be conducted through SPSS-24 software. DISCUSSION: The primary aim of the present trial is to determine the effect of vitamin D and/or omega-3 on glycemic indices, lipid profiles, psychological distress, blood pressure, and anthropometric indices in prediabetic women with hypovitaminosis D. The results from this trial will provide evidence on the efficacy of these two supplements for preventing or delaying the onset of type 2 diabetes in high-risk individuals. TRIAL REGISTRATION: Iran Clinical Trials Registry, IRCT20100130003226N17. Registered on 9 February 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Rajabi-Naeeni M, Dolatian M, Qorbani M, et al. The effect of co supplementation of omega-3 and vitamin D on cardio metabolic risk factors and psychological distress in reproductive-aged women with prediabetes and hypovitaminosis D: a study protocol for a randomized controlled trial. Trials. 2019. PMID: 31888762. doi:10.1186/s13063-019-3948-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。